MedPath

Sympathetic Activity in Post-injury Outcomes: Impact on Sleep and CaRdiovascular Health InvesTigation

Conditions
Hypertension
Cardiovascular Diseases
Arrythmia
Injury Traumatic
Sleep Disorder
Sympathetic Nervous System
Registration Number
NCT05971433
Lead Sponsor
Uniformed Services University of the Health Sciences
Brief Summary

The goal of this observational study is to learn about the long-term health of United States military service members who were injured during combat. The main questions it aims to examine are:

* How does the severity of a combat injury impact 1) cardiovascular risk, 2) the sympathetic nervous system and arrhythmias, 3) blood pressure, and 4) sleep disorders?

* Are self-reported mental health symptoms related to sympathetic nervous system hyperactivity, sleep disorders, and cardiovascular risk in combat-injured service members?

This study will recruit from a sample of participants in another research study called the Wounded Warrior Recovery Project (WWRP) who 1) agreed to be contacted about future research studies and 2) have a record of a combat injury within the Injury Severity Score ranges required for this study.

Participants will:

* Provide demographic information and a medical history review

* Visit a local laboratory for biometrics measurements and to provide blood and urine samples

* Wear an ambulatory electrocardiogram monitor for 24 hours per day for seven consecutive days

* Wear a home sleep test monitoring device for one night

* Wear a blood pressure monitor for 24 consecutive hours on the day after the home sleep test

At the end of the study, participants will be asked to mail back the home sleep test and blood pressure monitors. Prepaid package materials will be provided.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Enrolled in the Wounded Warrior Recovery Project (WWRP) and previously agreed to be contacted regarding future research
  • Able to complete the informed consent process, be mailed study devices, and complete laboratory draws within the United States
  • Age greater than or equal to 18 years
Exclusion Criteria
  • No Injury Severity Score or 3 < Injury Severity Score < 15
  • Unable to complete the informed consent process, be mailed study devices, and complete laboratory draws within the United States
  • Not enrolled in the WWRP or enrolled in the WWRP but did not agree to be contacted about future research

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Density of premature ventricular contractions (PVCs)7 days of wear

Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the density of PVCs (percentage of total heartbeats that are PVCs).

Frequency of ventricular tachycardia7 days of wear

Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of ventricular tachycardia.

Root mean square of successive differences (RMSSD)7 days of wear

Root mean square of successive differences (RMSSD) is a heart rate variability (HRV) time domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

Beat-to-beat QT variability index (QTVI)7 days of wear

Beat-to-beat QT variability index (QTVI) is a QT variability (QTV) measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

24-hour ambulatory blood pressure monitor (ABPM)24 hours

Blood pressure (diastolic and systolic) will be assessed using a 24-hour ABPM worn during the 24-hour period following the HST.

High sensitivity C-reactive protein (hs-CRP)Baseline

This inflammatory marker will be measured during laboratory testing.

Frequency of atrial flutter7 days of wear

Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of atrial flutter.

Frequency of atrial fibrillation7 days of wear

Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of atrial fibrillation.

Frequency of arrhythmias7 days of wear

Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of arrhythmias.

Low frequency power7 days of wear

Low frequency power (LF, 0.04 - 0.15 Hz) is a heart rate variability (HRV) frequency domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

Log-transformed QT variance (logQTv)7 days of wear

Log-transformed QT variance (logQTv) s a QT variability (QTV) measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

Presence of nocturnal hypoxemiaOne night

The presence of comorbid obstructive sleep apnea and/or nocturnal hypoxemia, will be evaluated with a home sleep study test device (HST) worn during the second or third study day

Insomnia Severity Index (ISI)Baseline

Participant-reported sleep characteristics will be assessed using the 7-item Insomnia Severity Index (ISI). Total scores range from 0 - 28, with higher scores indicating increased insomnia symptoms.

Heart rate7 days of wear

Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine heart rate.

High frequency power7 days of wear

High frequency power (HF, 0.15 - 0.4 Hz) is a heart rate variability (HRV) frequency domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

Brief Dissociative Experience Scale (DES-B)Baseline

Severity of dissociative experiences will be assessed using the 8-item DES-B survey. Total scores range from 0 - 32, with with higher scores indicating greater dissociative experience severity.

Standard deviation of beat-to-beat intervals (SDNN)7 days of wear

Standard deviation of beat-to-beat intervals (SDNN) is a heart rate variability (HRV) time domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

Posttraumatic Stress Disorder Checklist for Diagnostic and Statistics Manual of Mental Disorder 5 (PCL-5)Baseline

The severity of Posttraumatic Stress Disorder (PTSD) symptoms will be assessed by the PCL-5 20-question survey. Total scores range from 0 - 80, with higher scores indicating greater PTSD symptom severity.

Presence of obstructive sleep apneaOne night

The presence of comorbid obstructive sleep apnea and/or nocturnal hypoxemia, will be evaluated with a home sleep study test device (HST) worn during the second or third study day

8-item Patient Health Questionnaire depression scale (PHQ-8)Baseline

The severity of depressive symptoms will be measured by the eight-question PHQ-8 survey. Total scores range from 0 - 24, with with higher scores indicating greater depressive symptom severity.

Pittsburgh Sleep Quality Index (PSQI)Baseline

Participant-reported sleep characteristics will be assessed using the 19-item Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 - 21, with higher scores indicating worse sleep quality.

Epworth Sleepiness Scale (ESS)Baseline

Participant-reported sleep characteristics will be assessed using the 8-item Epworth Sleepiness Scale (ESS). Total scores range from 0 - 24, with higher scores indicating increased daytime sleepiness.

Body Mass IndexBaseline

Height and weight will be measured during laboratory visit and combined to report BMI in kg/m\^2.

Alanine aminotransferase (ALT/SGPT)Baseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Albumin:globulin (A:G) ratioBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Alkaline phosphatase, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Aspartate aminotransferase (AST/SGOT)Baseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Blood urea nitrogen (BUN)Baseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Blood urea nitrogen (BUN):creatinine ratioBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Carbon dioxide, totalBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Berlin Sleep QuestionnaireBaseline

Participant-reported sleep characteristics will be assessed using the 11-item Berlin Sleep Questionnaire. Scores will be calculated to determine if participants are "High Risk" or "Low Risk" for sleep apnea.

Blood PressureBaseline

Blood pressure (diastolic and systolic) will be recorded at the time of laboratory visit

Bilirubin, totalBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Hemoglobin A1C (HBA1C)Baseline

This laboratory test will be used to assess overall health outcomes.

Albumin, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Calcium, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Chloride, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Creatinine, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Potassium, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Sodium, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Estimated glomerular filtration rate (eGFR) calculationBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Globulin, totalBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Glucose, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

Cholesterol, totalBaseline

This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

Low-density lipoprotein (LDL) cholesterol (calculation)Baseline

This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

TriglyceridesBaseline

This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

Protein, total, serumBaseline

This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

High-density lipoprotein (HDL) cholesterolBaseline

This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

Albumin/creatinine ratio, random urineBaseline

This laboratory test will be used to assess overall health outcomes.

N-terminal pro b-type natriuretic peptide (NT-proBNP)Baseline

This laboratory test will be used to assess overall health outcomes.

Cystatin C with estimated glomerular filtration rate (eGFR)Baseline

This laboratory test will be used to assess overall health outcomes.

Very low-density lipoprotein (VLDL) cholesterol (calculation)Baseline

This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Uniformed Services University of the Health Sciences

🇺🇸

Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath